Summary
In about 2/3 of the cases studied (152 patients), the combination of deprenyl and the substitution-therapy has a favourable effect as it tends to normalize motor activity. Although the administering of deprenyl renders neither L-Dopa nor the decarboxylase inhibitor superfluous, their side effects can be slightly reduced as their dose is reduced. Therefore it is advised to give all patients a trial with this drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W. The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J. Neural Transm.36, 303–326 (1975).
Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M. B. H. Implications of combined treatment with Madopar® and deprenil in Parkinson's disease: a long-term study. Lanceti, 434–443 (1977).
Glover, V., Sandler, M., Owen, F., Riley, G. J. Dopamine is a monoamine oxidase B substrate in man. Nature (London)265, 80–81 (1977).
Knoll, J., Vizi, E. S., Somogyi, G. Phenylisopropylmethylpropinylamine (E-250) a monoamino oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelforschung18, 109–112 (1968).
Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B. H. Deprenyl in Parkinson's disease. Lancetii, 791–796 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Csanda, E., Antal, J., Antóny, M. et al. Experiences with L-deprenyl in Parkinsonism. J. Neural Transmission 43, 263–269 (1978). https://doi.org/10.1007/BF01246963
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01246963